Welcome to our dedicated page for Can-Fite BioPharma Ltd. SEC filings (Ticker: CANF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Can-Fite BioPharma Ltd. filings document foreign-private-issuer disclosures for a clinical-stage biotechnology company whose American Depositary Shares trade under CANF. Its Form 6-K reports furnish press releases, annual and special meeting materials, proxy statements, voting instruction cards for ADS holders, and shareholder-vote results.
The company’s regulatory record covers clinical and regulatory updates for A3AR drug candidates, Namodenoson and Piclidenoson patent matters, partner-related development disclosures, operating and financial results, capital-structure items, registration-statement incorporation for Form S-8 and Form F-3 filings, governance matters, and risks connected to drug development and public-company financing.
Can-Fite BioPharma Ltd., an Israel-based foreign private issuer, reports that its Annual General Meeting of Shareholders held on June 4, 2026 approved all five proposals presented to shareholders. These proposals were previously detailed in the company’s Notice and Proxy Statement dated April 23, 2026, which had been furnished to the SEC on Form 6-K.
Can-Fite BioPharma Ltd. furnished a corporate update highlighting early clinical and mechanistic data for its drug namodenoson in pancreatic cancer. In an ongoing Phase 2a monotherapy study, enrollment is complete and several patients have shown prolonged disease control, including one patient remaining on therapy and follow-up for about 16 months.
The company emphasizes namodenoson’s differentiated mechanism, noting preclinical anti-tumor activity via modulation of RAS, Wnt/β-catenin and NF-κB signaling pathways, which are relevant in RAS-driven malignancies such as pancreatic ductal adenocarcinoma. Namodenoson is a selective A3 adenosine receptor agonist with a reported favorable safety profile and Orphan Drug Designation for pancreatic cancer.
Can-Fite also recaps its broader pipeline. Piclidenoson is in a pivotal Phase 3 psoriasis trial, while namodenoson is in a Phase III trial for hepatocellular carcinoma and a Phase 2b trial for MASH. Across programs, the company reports clinical experience in over 1,600 patients to date.
Can-Fite BioPharma Ltd. held its 2026 Annual General Meeting of Shareholders on May 28, 2026, but the meeting was adjourned because there were not enough shareholders present to meet the required quorum. The meeting is scheduled to reconvene on June 4, 2026 at 3:00 p.m. Israel time at the company’s offices in Ramat Gan, Israel.
Can-Fite BioPharma Ltd. furnished a report highlighting a new peer-reviewed publication on its lead drug candidate Piclidenoson in canine osteoarthritis. The article in Frontiers in Veterinary Science describes a study where oral Piclidenoson produced statistically significant improvements in mobility and pain in dogs, with a favorable safety profile.
Piclidenoson is being developed for veterinary use by Vetbiolix under a licensing agreement potentially valued at up to $325 million in upfront, milestone and royalty payments, and is currently in an advanced Phase 2 clinical study in dogs. Can-Fite also reiterates its broader clinical pipeline, including Piclidenoson in psoriasis Phase 3 trials and Namodenoson in multiple Phase II/III studies in liver and oncology indications, all supported by safety experience in over 1,600 patients.
Can-Fite BioPharma Ltd. reported encouraging Phase 2a results for Namodenoson in advanced pancreatic cancer and plans a Phase 2b study combining the drug with immunotherapy. The Phase 2a trial showed a favorable safety profile, treatment extending beyond 16 months in some patients, stable disease in over 30% of evaluable patients, and 35% of patients remaining on therapy and follow up. The company intends to discuss the Phase 2b study design and potential partnerships with leading oncology companies at the BIO International Convention. Namodenoson has Orphan Drug Designation from the U.S. FDA for pancreatic cancer and is also in trials for liver cancer and MASH.
Can-Fite BioPharma Ltd. reported positive Phase 2a data for its drug namodenoson in advanced pancreatic cancer. In this fully enrolled, 20-patient open-label study, namodenoson showed a favorable safety profile and preliminary signs of durable disease stabilization in heavily pretreated patients.
About 35% of patients remain on therapy, including one treated for more than 16 months, suggesting potential for longer-term benefit in this difficult-to-treat setting. The trial met its primary safety endpoint, with no new safety signals and consistency with prior namodenoson experience. Full efficacy analyses, including progression-free and overall survival, are planned, with top-line results expected to be presented at an upcoming clinical conference.
Can-Fite BioPharma Ltd. will hold its 2026 Annual General Meeting of Shareholders on May 28, 2026 at its offices in Ramat Gan, Israel. Shareholders of record as of May 4, 2026 may vote.
Items include re-electing director Abraham Sartani, increasing authorized share capital from 14,000,000 to 30,000,000 ordinary shares, and granting 24,000 stock options each to Chairman Dr. Pnina Fishman and CEO/CFO Motti Farbstein. Investors will also vote on re-appointing Kost Forer Gabbay & Kasierer (Ernst & Young Global member) as independent auditors for 2026 and authorizing the audit committee to set their compensation, and will review the auditor’s report and consolidated financial statements for the year ended December 31, 2025.
Can-Fite BioPharma Ltd. director Tamir Ilan reported his initial beneficial ownership, consisting of options to purchase 16,000 Ordinary Shares. These options have an exercise price of $2.25 per share and expire on April 25, 2036.
None of the options are currently vested. All 16,000 options vest in sixteen equal quarterly installments from April 25, 2026 through January 25, 2030, subject to his continued service with the company. The options were granted under Can-Fite’s share option plans and are held through a trustee to qualify for tax benefits under Section 102 of the Israeli Tax Ordinance. The exercise price was originally set at NIS 6.767 and is presented in U.S. dollars using a Bank of Israel exchange rate of NIS 3.003 = USD 1.00 as of April 20, 2026.
Can-Fite BioPharma Ltd. director Regev Guy filed an initial ownership statement showing direct holdings of options to purchase Ordinary Shares and a small number of shares. He reports options over 16,000 shares at an exercise price of $2.18 per share plus several smaller, higher-priced option grants and 8 Ordinary Shares. The options were granted under the company’s share option plans, with some fully vested and others vesting in scheduled quarterly installments through 2030.